Related Experiment Video

Updated: Sep 4, 2026

A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs
04:15

A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs

Published on: February 2, 2024

[Eptifibatide (Integrilin)]

L Holmvang1, P Grande

  • 1H:S Rigshospitalet, Hjertecentret, medicinsk afdeling B.

Ugeskrift for Laeger
|February 24, 2001
PubMed

Insights

Eptifibatide (Integrilin) effectively inhibits platelet aggregation by blocking glycoprotein IIb/IIIa receptors. This medication reduces coronary events in specific acute coronary syndrome patients, supported by clinical trials and cost-benefit data.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Platelet aggregation is a key factor in acute coronary syndromes.
  • Glycoprotein IIb/IIIa receptors play a critical role in platelet activation.
  • Eptifibatide is a known inhibitor of this receptor pathway.

Purpose of the Study:

  • To summarize the established indications for eptifibatide (Integrilin) use.
  • To review recent clinical trial data supporting its efficacy.
  • To analyze the cost-benefit aspects of eptifibatide therapy.

Main Methods:

  • Review of recent clinical trials on eptifibatide.
  • Analysis of cost-benefit studies related to its application.
  • Synthesis of data on glycoprotein IIb/IIIa receptor blockade.

Main Results:

  • Eptifibatide demonstrates effectiveness in reducing coronary events.
  • Its use is indicated for patients with acute coronary syndromes without ST-segment elevation.
  • Clinical data and economic analyses support its therapeutic role.

Conclusions:

  • Eptifibatide is a valuable therapeutic agent for specific acute coronary syndrome patients.
  • Its mechanism involves specific glycoprotein IIb/IIIa receptor blockade.
  • Evidence from trials and cost-benefit analyses validates its clinical indications.

More Related Videos

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Related Concept Videos

Integrins01:10

Integrins

Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...